Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Completed 3Unknown 2Terminated 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Polycystic Ovary Syndrome 1Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × empagliflozin × Clear all
NCT06103279 2023-10-26

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Ain Shams University

Phase 2/3 Unknown
40 enrolled
Tumor-Agnostic

Neoplasms

NCT05200793 2022-01-21

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Alexandria University

Phase 4 Unknown
75 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡